September 16, 2011
Over the past year, ACRIA has been working with key pharmaceutical companies, colleagues in San Francisco (Drs. Lalezari and Deeks), and a community HIV activist (Nelson Vergel) to develop a unique, multi-drug expanded access program (or 'salvage' protocol) for persons with HIV who are resistant to all currently-approved classes of antiretrovirals(ARVs).
With the support of the FDA, this protocol will permit the use of two or more experimental agents currently in late phase II or III clinical trials, but not yet FDA-approved, together with approved ARVs in a treatment regimen. We hope to begin enrolling patients in New York and San Francisco by early 2012.
Before we begin, it would be helpful to know how many patients might be eligible for such a protocol. Therefore, we would greatly appreciate your participation in a very short survey (4 questions – 90 seconds!) at: https://www.surveymonkey.com/s/MDEAPNYC
Thank you for your assistance. We will be in touch very soon regarding our progress on this salvage protocol.
Jerry Ernst, MD
Medical Director, Amida Care and ACRIA
Executive Director, ACRIA
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.